EpiTan Australia will start a UK trial of a new topical formulation of Melanotan(I) in April. Melanotan 2 is a melanocyte-stimulating hormone analogue used to prevent sun damage. It stimulates the production of melanin, darkens the skin and protects the skin from UV rays
shoot. It is being developed into an implantable dosage form for launch in Australia in late 2016 or early 2017. But EpiTan says topical sprays are much easier to use and distribute the drug more evenly over the body. The UK study will involve approximately 30 healthy volunteers receiving increasing doses of 1ml of the solution, sprayed on the arms daily for 10 days.

For melanotan 2 infos: melanotan 2 supplier

Topical minoxidil for women launched in Japan
Taisho will launch a topical drug in Japan at the end of March to treat androgenic alopecia (hair loss) in women, following the recent direct OTC approval of minoxidil. The 1g/100ml RiUPLady 60ml bottle retails for 5,775 yen ($55) per bottle. For women over 20 years of age, minoxidil is applied in a 1-ml dose twice daily to the affected area. By expanding the existing female hair growth market, Taisho is targeting sales of 5 billion yen in the first year, a market worth about 3 billion yen. The male preparation was launched in mid-1999, with sales of 30 billion yen in the first year, and more than 30 million bottles have been sold so far.